Evaluation of change in metabolome caused by comprehensive diabetes treatment: A prospective observational study of diabetes inpatients with gas chromatography/mass spectrometry‐based non‐target metabolomic analysis

• Published in: Journal of diabetes investigation Vol. 12; no. 12; pp. 2232 - 2241
• Main Authors: Taya, Naohiro, Katakami, Naoto, Omori, Kazuo, Arakawa, Shoya, Hosoe, Shigero, Watanabe, Hirotaka, Takahara, Mitsuyoshi, Miyashita, Kazuyuki, Nishizawa, Hitoshi, Matsuoka, Taka‐Aki, Furuno, Masahiro, Bamba, Takeshi, Iida, Junko, Fukusaki, Eiichiro, Shimomura, Iichiro
• Format: Journal Article
• Language: English
• Published: Japan John Wiley & Sons, Inc 01.12.2021; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Aged; Amino acids; Amino Acids - blood; Blood pressure; Case-Control Studies; Chromatography; Cluster Analysis; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes treatment; Fasting; Fasting - blood; Female; Gas chromatography; Gas Chromatography-Mass Spectrometry; Glutamine; Glycemic Control - methods; Glycemic Control - statistics & numerical data; Humans; Hyperglycemia; Hypertension; Inpatients - statistics & numerical data; Laboratory testing; Lipids; Lysine; Male; Mass spectrometry; Mass spectroscopy; Metabolic disorders; Metabolites; Metabolome; Metabolomics; Metabolomics - methods; Methionine; Middle Aged; Monosaccharides; Monosaccharides - blood; Observational studies; Original; Patients; Peptides; Plasma; Plasma levels; Principal Component Analysis; Principal components analysis; Proline; Prospective Studies; Pyroglutamic acid; Scientific imaging; Standard deviation; Statistical analysis; Threonine; Values; Vital signs; Young Adult; Japan; Metabolomics; Amino acids; Diabetes treatment
• ISSN: 2040-1116; 2040-1124
• DOI: 10.1111/jdi.13600

Aims/Introduction Diabetes patients develop a variety of metabolic abnormalities in addition to hyperglycemia. However, details regarding change in various metabolites after comprehensive diabetes treatment remain unknown. This study aimed to identify the short‐term change in metabolome in inpatients who were subject to comprehensive diabetes treatment, using gas chromatography/mass spectrometry‐based non‐target metabolomics techniques. Materials and Methods Participants of the present study were randomly recruited from the patients with type 2 diabetes hospitalized due to problems with glycemic control (n = 31) and volunteers without diabetes (n = 30), both of whom were aged between 20 and 75 years. A metabolomic analysis of fasting plasma samples on the 2nd (pre‐treatment) and 16th hospital (post‐treatment) day with gas chromatography/mass spectrometry using a multiple reaction monitoring mode was carried out. Results A principal component analysis showed that metabolome of fasting plasma was different between individuals with and without diabetes. The metabolome of fasting plasma in diabetes patients after treatment was different from that of pre‐treatment, as well as individuals without diabetes. Many amino acids (proline, glycine, serine, threonine, methionine, pyroglutamic acid, glutamine and lysine) were significantly increased by >10% after administering the inpatient diabetes treatment. A hierarchical clustering analysis showed that in the case of patients with markedly decreased monosaccharide levels and increased 1,5‐anhydroglucitol, the levels of amino acids increased more significantly. Conclusions After a 2‐week comprehensive treatment, the plasma levels of various amino acids increased in conjunction with the reduction in monosaccharide levels in poorly controlled type 2 diabetes patients. This study aimed to identify the short‐term change in metabolome in inpatients who were subject to comprehensive diabetes treatment, using gas chromatography/mass spectrometry‐based non‐target metabolomics techniques. After a 2‐week comprehensive treatment, the plasma levels of various amino acids increased in conjunction with the reduction in monosaccharide levels in poorly controlled type 2 diabetes patients.